2. Signaling Pathways
  3. GPCR/G Protein
  4. GPR109A
  5. GPR109A Agonist

GPR109A Agonist

GPR109A Agonists (13):

Cat. No. Product Name Effect Purity
  • HY-103252
    Monomethyl fumarate
    		Agonist 99.95%
    Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease.
  • HY-10680
    MK-6892
    		Agonist 99.43%
    MK-6892 is a potent, selective, and full agonist for the high affinity nicotinic acid (NA) receptor GPR109A. Ki and GTPγS EC50 of MK-6892 on the Human GPR109A is 4 nM and 16 nM, respectively.
  • HY-13008
    MK-0354
    		Agonist 99.73%
    MK-0354 is a specific GPR109a receptor agonist with EC50 values of 1.65 μM and 1.08 μM for hGPR109a and mGPR109a, respectively. MK-0354 can be used in liver cancer research.
  • HY-119222
    GSK256073
    		Agonist 99.39%
    GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
  • HY-103252S2
    Monomethyl fumarate-d2
    		Agonist 98.19%
    Monomethyl fumarate-d2 is a deuterium labeled Monomethyl fumarate (HY-103252). Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF) (HY-17363), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease.
  • HY-176817
    GPR109 receptor agonist-3
    		Agonist
    GPR109 receptor agonist-3 is an orally active GPR109 receptor agonist, with an IC50 of 310 nM. GPR109 receptor agonist-3 retains the antioxidation and cytoprotection of Lipoic acid (HY-18733). GPR109 receptor agonist-3 reduces total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and increases high-density lipoprotein cholesterol (HDL-C) in high-fat diet-fed rats. GPR109 receptor agonist-3 can be used for the study of atherosclerosis.
  • HY-107579
    Acifran
    		Agonist 99.25%
    Acifran (AY 25712), an antihyperlipidemic agent, is an orally active agonist of GPR109A (HM74A) and GPR109B, the high and low affinity receptors for Niacin.
  • HY-107580
    GPR109 receptor agonist-1
    		Agonist 99.94%
    GPR109 receptor agonist-1 (Compound 3a) is a highly selective agonist of the human orphan G-protein-coupled receptor GPR109b, with the pEC50 of 6.4. GPR109 receptor agonist-1 can be used for the research of cardio-metabolic diseases.
  • HY-W095200
    GPR109 receptor agonist-2
    		Agonist 99.08%
    GPR109 receptor agonist-2 (Compound 5) is a selective GPR109a agonist with a pEC50 of 5.53.
  • HY-103252R
    Monomethyl fumarate (Standard)
    		Agonist
    Monomethyl fumarate (Standard) is the analytical standard of Monomethyl fumarate. This product is intended for research and analytical applications. Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[1][2][3].
  • HY-107579R
    Acifran (Standard)
    		Agonist
    (2S,5R,6R)-Ticarcillin (disodium) (Standard) is the analytical standard of (2S,5R,6R)-Ticarcillin (disodium). This product is intended for research and analytical applications. (2S,5R,6R)-Ticarcillin disodium is an injectable antibiotic for the treatment of Gram-negative bacteria, particularly Pseudomonas aeruginosa. It is also one of the few antibiotics capable of treating Stenotrophomonas maltophilia infections.
  • HY-119222A
    GSK256073 tris
    		Agonist
    GSK256073 tris is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 tris acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
  • HY-103252S1
    Monomethyl fumarate-d5
    		Agonist
    Monomethyl fumarate-d5 is deuterium labeled Monomethyl fumarate (HY-103252). Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF) (HY-17363), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease.